



Catalog Number:	MC11021	Product Type:	Small Molecule
Bio-Activity:	Anticonvulsant; Cognition enhancer	CAS #:	106308-44-5
Research Categories:	Neuroscience	Chemical Name:	1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide
Solubility:	Soluble in DMSO (up to 10 mg/ml)	Molecular Formula:	C10H8F2N4O2
Purity:	> 98%	Molecular Weight:	238.19
Format:	Powder	Ship Temp:	Ambient
Storage:	-20°C		

Application Notes

Description/Data:

Rufinamide is an anticonvulsant medication with clinical applications (1). It inhibits Nav1.1 and Nav1.6 activation (2). In gerbils, Rufinamide improved cognitive function and increased neurogenesis by increasing IGF-1, IGF-1R, and p-CREB (3).

References:

- 1) Hakimian et al. (2007), Rufinamide: a new anti-epileptic medication; *Expert Opin.Pharmacother.* 8 1931
- 2) Gilchrist et al. (2014), Nav1.1 Modulation by a Novel Triazole Compound Attenuates Epileptic Seizures in Rodents; *ACS Chem.Biol.* 9 1204
- 3) Chen et al. (2018), Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB; *Chem.Biol.Interact* 286 71

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012